KR102494294B1 - Parp1, pap2 및/또는 튜블린의 저해제로서 암 치료에 유용한 프탈라진 유도체 - Google Patents

Parp1, pap2 및/또는 튜블린의 저해제로서 암 치료에 유용한 프탈라진 유도체 Download PDF

Info

Publication number
KR102494294B1
KR102494294B1 KR1020197002267A KR20197002267A KR102494294B1 KR 102494294 B1 KR102494294 B1 KR 102494294B1 KR 1020197002267 A KR1020197002267 A KR 1020197002267A KR 20197002267 A KR20197002267 A KR 20197002267A KR 102494294 B1 KR102494294 B1 KR 102494294B1
Authority
KR
South Korea
Prior art keywords
cancer
exemplary embodiment
unsubstituted
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197002267A
Other languages
English (en)
Korean (ko)
Other versions
KR20190033534A (ko
Inventor
체 창
싸바 제이. 페토
데이비드 엠. 자브론스
하싼 렘자발-알라위
Original Assignee
더 리전트 오브 더 유니버시티 오브 캘리포니아
아틀라스메드엑스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리전트 오브 더 유니버시티 오브 캘리포니아, 아틀라스메드엑스 인코포레이티드 filed Critical 더 리전트 오브 더 유니버시티 오브 캘리포니아
Publication of KR20190033534A publication Critical patent/KR20190033534A/ko
Application granted granted Critical
Publication of KR102494294B1 publication Critical patent/KR102494294B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197002267A 2016-06-24 2017-06-23 Parp1, pap2 및/또는 튜블린의 저해제로서 암 치료에 유용한 프탈라진 유도체 Active KR102494294B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662354449P 2016-06-24 2016-06-24
US62/354,449 2016-06-24
US201662426095P 2016-11-23 2016-11-23
US62/426,095 2016-11-23
PCT/US2017/039119 WO2017223516A1 (en) 2016-06-24 2017-06-23 Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer

Publications (2)

Publication Number Publication Date
KR20190033534A KR20190033534A (ko) 2019-03-29
KR102494294B1 true KR102494294B1 (ko) 2023-01-31

Family

ID=59297390

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197002267A Active KR102494294B1 (ko) 2016-06-24 2017-06-23 Parp1, pap2 및/또는 튜블린의 저해제로서 암 치료에 유용한 프탈라진 유도체

Country Status (15)

Country Link
US (3) US11072600B2 (enExample)
EP (1) EP3475272B1 (enExample)
JP (2) JP7033588B2 (enExample)
KR (1) KR102494294B1 (enExample)
CN (1) CN109843874B (enExample)
AU (1) AU2017280334C1 (enExample)
ES (1) ES2964531T3 (enExample)
HU (1) HUE066216T2 (enExample)
IL (1) IL263917B (enExample)
MX (2) MX387726B (enExample)
PL (1) PL3475272T3 (enExample)
PT (1) PT3475272T (enExample)
SG (1) SG11201811393WA (enExample)
WO (1) WO2017223516A1 (enExample)
ZA (2) ZA201808562B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3298005B1 (en) 2015-05-21 2024-01-24 The Regents of The University of California Anti-cancer compounds
EP3383852A4 (en) * 2015-11-30 2019-08-28 Children's Medical Center Corporation COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP3475272B1 (en) 2016-06-24 2023-09-13 The Regents of The University of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
JP7372253B2 (ja) * 2018-04-05 2023-10-31 ノビガ・リサーチ・エービー 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ
CN112574122B (zh) * 2019-09-27 2024-05-31 上海天慈国际药业有限公司 一种奥拉帕尼关键中间体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3401171A (en) 1966-03-11 1968-09-10 Smithkline Corp 2-amidobenzimidazoles
SU1019810A1 (ru) 1981-07-28 1991-04-07 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Метиловый эфир 5(6)-[1-(2Н)-фталазинонил-4]-1Н-бензимидазолил-2-карбаминовой кислоты, обладающий антигельминтной активностью
SU1218649A1 (ru) 1984-09-19 1991-04-30 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Способ получени метилового эфира 5(6)-[1(2Н)-фталазинонил-4-]-1Н-бензимидазолил-2-карбаминовой кислоты формулы
JP2002502844A (ja) 1998-02-03 2002-01-29 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用
KR20010101675A (ko) 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
DE19907813A1 (de) 1999-02-24 2000-08-31 Boehringer Ingelheim Pharma Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
EP1633724B1 (en) 2003-03-12 2011-05-04 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2005112932A2 (en) 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
CN101291928A (zh) * 2005-10-19 2008-10-22 库多斯药物有限公司 4-杂芳甲基取代的酞嗪酮衍生物
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
JP5492183B2 (ja) * 2008-03-27 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン
CA3012137A1 (en) 2010-01-29 2011-08-04 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CA2875025C (en) 2011-05-31 2021-08-03 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
KR101546743B1 (ko) * 2012-01-16 2015-08-24 한국과학기술원 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물
AU2013368842B2 (en) * 2012-12-31 2015-11-12 Cadila Healthcare Limited Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
EP3475272B1 (en) * 2016-06-24 2023-09-13 The Regents of The University of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D.V.Ferraris, Journal of Medicinal Chemistry，2010, 53(12), p.4561-4584
T. Zaremba, N.J.Curtin, Anti-Cancer Agents in Medicinal Chemistry，2007, 7(5), p.515-523

Also Published As

Publication number Publication date
ZA201808562B (en) 2023-12-20
JP7033588B2 (ja) 2022-03-10
US11072600B2 (en) 2021-07-27
EP3475272B1 (en) 2023-09-13
SG11201811393WA (en) 2019-01-30
WO2017223516A1 (en) 2017-12-28
IL263917B (en) 2022-07-01
BR112018076821A2 (pt) 2019-04-02
US10640493B2 (en) 2020-05-05
MX2018015893A (es) 2019-08-01
AU2017280334A1 (en) 2019-01-17
IL263917A (en) 2019-02-28
HUE066216T2 (hu) 2024-07-28
JP2022037004A (ja) 2022-03-08
US20190352283A1 (en) 2019-11-21
US20220402894A1 (en) 2022-12-22
MX387726B (es) 2025-03-18
US12145925B2 (en) 2024-11-19
JP2019522681A (ja) 2019-08-15
ZA202301066B (en) 2024-05-30
CN109843874A (zh) 2019-06-04
CA3029004A1 (en) 2017-12-28
PL3475272T3 (pl) 2024-04-29
CN109843874B (zh) 2022-05-27
EP3475272A1 (en) 2019-05-01
PT3475272T (pt) 2023-12-15
ES2964531T3 (es) 2024-04-08
US20190337928A1 (en) 2019-11-07
MX2021013641A (es) 2022-01-06
KR20190033534A (ko) 2019-03-29
AU2017280334B2 (en) 2021-07-29
AU2017280334C1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
US12145925B2 (en) Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
CN111315747B (zh) 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
EP3575301A1 (en) Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
US20240190871A1 (en) Krasg12d inhibitor, preparation method therefor and application thereof
CN107835811B (zh) 苯胺嘧啶衍生物及其用途
US20240182470A1 (en) Krasg12c mutant protein inhibitor, prearation and use thereof
JP7602630B2 (ja) アリールリン酸化物化合物およびその使用
JP2023109924A (ja) ジヒドロイミダゾピラジノン化合物、該化合物を含む組成物およびその使用
CN115340559A (zh) Shp2磷酸酶杂环类抑制剂的制备及其应用
CN115073450A (zh) Krasg12c突变蛋白抑制剂的制备及其应用
US11708352B2 (en) Anti-cancer compounds
TW201331206A (zh) 作為ｃ－Ｍｅｔ抑制劑的新型稠環雜環衍生物
CA3174865A1 (en) Quinazoline compound and preparation method, application, and pharmaceutical composition thereof
CN111377873A (zh) 氨基嘧啶化合物及其制备方法和用途
JP2024516194A (ja) Ｐｄ１／ｐｄ－ｌ１阻害剤としての化合物及びその方法
CA3029004C (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
HK40002445B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
HK40002445A (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
CN116783166B (zh) 二甲酰胺类化合物、其制备方法及其在医药上的应用
BR112018076821B1 (pt) Compostos ou sal, hidrato ou solvato dos mesmos, seus usos, formulação farmacêutica e método in vitro de inibição de parp1 e/ou parp2 e/ou tubulina
CN105348299B (zh) 作为raf激酶抑制剂的稠合三环化合物
KR20230104163A (ko) 암 치료용 벤조[h]퀴나졸린-4-아민 및 티에노[3,2-h]퀴나졸린-4-아민 유도체
HK1250164B (zh) 苯胺嘧啶衍生物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200623

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220127

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220503

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221027

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230127

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230127

End annual number: 3

Start annual number: 1

PG1601 Publication of registration